Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C J Wikstrand

Showing results (81-90 of 84) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 84 results.
Proceedings of the National Academy of Sciences of the United States of America|June 15, 2000
Unarmed, tumor-specific monoclonal antibody effectively treats brain tumorsJ H Sampson, L E Crotty, S Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2000
Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomasI Cokgor, G Akabani, C T Kuan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 1998
Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial resultsD D Bigner, M T Brown, A H Friedman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 1996
Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial resultsM T Brown, R E Coleman, A H Friedman, et al.
Pageof 9

Showing results (81-90 of 84) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 84 results.
Proceedings of the National Academy of Sciences of the United States of America|June 15, 2000
Unarmed, tumor-specific monoclonal antibody effectively treats brain tumorsJ H Sampson, L E Crotty, S Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2000
Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomasI Cokgor, G Akabani, C T Kuan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 1998
Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial resultsD D Bigner, M T Brown, A H Friedman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 1996
Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial resultsM T Brown, R E Coleman, A H Friedman, et al.
Pageof 9